Key Executive Severance Agreement Sample Contracts
PONIARD PHARMACEUTICALS, INC. KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • February 11th, 2010 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Key Executive Severance Agreement (this “Agreement”), dated as of February 5, 2010, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10 hereof, the “Company”), and Michael S. Perry, DVM, Ph.D. (the “Executive”).
NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • February 23rd, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this "Agreement"), dated as of February 28, 2003, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 10, the "Company"), and Linda Findlay (the "Executive").
THIS MASTER AMENDMENT to the Key Executive Severance Agreement dated July 10, 1990, as amended April 18, 1995; the Key Executive Severance Agreement Stock Supplement dated July 10, 1990; and the Key Executive Severance Pension and SERP Supplement...Key Executive Severance Agreement • April 14th, 1998 • Blessings Corp • Unsupported plastics film & sheet
AMENDMENT NO. 1 TO AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • February 11th, 2010 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”), dated as of February 5, 2010, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (the “Company”), and RONALD A. MARTELL (the “Executive”).
KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • January 3rd, 2008 • Ducommun Inc /De/ • Aircraft parts & auxiliary equipment, nec • California
This Key Executive Severance Agreement (the “Agreement”) is dated as of [date], and is made by and between Ducommun Incorporated, a Delaware corporation (the “Company”), and [name], who is presently [position] of the Company (the “Executive”).
NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • February 23rd, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances • Washington
This Key Executive Severance Agreement (VP) (this "Agreement"), dated as of May 13, 2003, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 10, the "Company"), and KAREN AUDITORE-HARGREAVES (the "Executive").
AMENDMENT NO. 1 TO NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 10th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Amendment, dated as of March 30, 2005, is entered into by and between NEORX CORPORATION (the “Company”) and LINDA FINDLAY (the “Executive”) with respect to the Key Executive Severance Agreement between the Company and the Executive dated as of February 28, 2003 (the “Agreement”) as follows:
KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • January 27th, 2017 • Ducommun Inc /De/ • Aircraft parts & auxiliary equipment, nec • California
This Key Executive Severance Agreement (the “Agreement”) is dated as of [date], and is made by and between Ducommun Incorporated, a Delaware corporation (the “Company”), and [name] who is presently [position] of the Company (the “Executive”).
PROCYTE CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • August 12th, 2004 • Procyte Corp /Wa/ • Pharmaceutical preparations
This Key Executive Severance Agreement (this “Agreement”), dated and effective as of July 1, 2004, is between PROCYTE CORPORATION, a Washington corporation (the “Company”), and JOHN F. CLIFFORD (the “Executive”).
AMENDMENT NO. 1 TO NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 10th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Amendment, dated as of March 30, 2005, is entered into by and between NEORX CORPORATION (the “Company”) and ANNA WIGHT (the “Executive”) with respect to the Key Executive Severance Agreement between the Company and the Executive dated as of February 28, 2003 (the “Agreement”) as follows:
AMENDMENT NO. 1 TO NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 10th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Amendment, dated as of March 30, 2005, is entered into by and between NEORX CORPORATION (the “Company”) and KAREN AUDITORE-HARGREAVES (the “Executive”) with respect to the Key Executive Severance Agreement between the Company and the Executive dated as of May 13, 2003 (the “Agreement”) as follows:
AMENDMENT NO. 1 TOKey Executive Severance Agreement • May 10th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Amendment, dated as of March 30, 2005, is entered into by and between NEORX CORPORATION (the “Company”) and SUSAN D. BERLAND (the “Executive”) with respect to the Key Executive Severance Agreement between the Company and the Executive dated as of October 25, 2004 (the “Agreement”) as follows: